

1 **Self-reported and physiological reactions to the third BNT162b2 mRNA**

2 **COVID-19 (booster) vaccine dose**

3 **Running title: Reactions to the third Pfizer COVID-19 (booster) vaccine**

4 **dose** Merav Mofaz, MSc<sup>1</sup>, Matan Yechezkel, MSc<sup>1</sup>, Grace Guan<sup>2</sup>, Margaret L. Brandeau, PhD<sup>2</sup>, Tal

5 Patalon, MD<sup>3</sup>, Sivan Gazit, MD<sup>3</sup>, Dan Yamin, PhD<sup>1,4,+</sup>, and Erez Shmueli, PhD<sup>1,5,+,\*</sup>

6 <sup>1</sup>Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel.

7 <sup>2</sup>Department of Management Science and Engineering, Stanford University, Stanford CA, USA.

8 <sup>3</sup>Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.

9 <sup>4</sup>Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel.

10 <sup>5</sup>MIT Media Lab, Cambridge MA, USA.

11 <sup>+</sup>Equal contribution

12 <sup>\*</sup>Corresponding author. Email: shmueli@tau.ac.il

13 **Keywords:** COVID-19 vaccine, third COVID-19 dose, booster vaccine, BNT162b2, adverse effects,

14 wearables

15 **Abstract**

16 **Background:** The rapid rise in hospitalizations associated with the Delta-driven COVID-  
17 19 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government  
18 to initialize a national third (booster) COVID-19 vaccination campaign in early August  
19 2021, offering the BNT162b2 mRNA vaccine to individuals who received their second  
20 dose over five months ago. However, the safety of the third (booster) dose has not been  
21 fully established yet.

22 **Objective:** Evaluate the short-term, self-reported and physiological reactions to the third  
23 BNT162b2 mRNA COVID-19 (booster) vaccine dose.

24 **Design:** A prospective observational study, in which participants are equipped with a  
25 smartwatch and fill in a daily questionnaire via a dedicated mobile application for a period  
26 of 21 days, starting seven days before the vaccination.

27 **Setting:** An Israel-wide third (booster) vaccination campaign.

28 **Participants:** A group of 1,609 (18+ years of age) recipients of at least one dose of the  
29 BNT162b2 vaccine between December 20, 2020, and September 15, 2021, out of a larger  
30 cohort of 2,912 prospective study participants. 1,344 of the participants were recipients of  
31 the third vaccine dose.

32 **Measurements:** Daily self-reported questionnaires regarding local and systemic reactions,  
33 mood level, stress level, sport duration, and sleep quality. Heart rate, heart rate variability  
34 and blood oxygen saturation level were continuously measured by Garmin Vivosmart 4  
35 smartwatches.

36 **Results:** The extent of systemic reactions reported following the third (booster) dose  
37 administration is similar to that reported following the second dose (p-value=0.305) and

38 considerably greater than that reported following the first dose (p-value<0.001). Our  
39 analyses of self-reported well-being indicators as well as the objective heart rate and heart  
40 rate variability measures recorded by the smartwatches further support this finding.  
41 Focusing on the third dose, reactions were more apparent in younger participants (p-  
42 value<0.01), in women (p-value<0.001), and in participants with no underlying medical  
43 conditions (p-value<0.001). Nevertheless, reported reactions and changes in physiological  
44 measures returned to their baseline levels within three days from inoculation with the third  
45 dose.

46 **Limitations:** Participants may not adequately represent the vaccinated population in Israel  
47 and elsewhere.

48 **Conclusion:** Our work further supports the safety of a third COVID-19 BNT162b2 mRNA  
49 (booster) vaccine dose from both a subjective and an objective perspective, particularly in  
50 individuals 65+ years of age and those with underlying medical conditions.

51 **Primary funding source:** European Research Council (ERC) project #949850.

52

### 53 **Introduction:**

54 The SARS-CoV-2 Delta variant (also termed variant B.1.617.2) was discovered in October  
55 2020, in India, and was designated as a variant of concern by the World Health  
56 Organization (WHO) in May 2021 (1–3). Since its discovery, it has spread worldwide and  
57 has rapidly become the most dominant variant in many countries (4–7). Although the  
58 BNT162b2 COVID-19 vaccine is highly effective against the Alpha variant (8), recent  
59 studies show that the effectiveness of the Pfizer-BioNTech vaccines is notably lower  
60 against the Delta variant – 88% compared to 93.7% against the Alpha variant (9–12).

61 Moreover, recent evidence shows that fully vaccinated individuals infected with the virus  
62 can easily transmit it further, as their peak viral burden is similar to that observed in  
63 unvaccinated individuals (7,10). In Israel, the Delta variant has accelerated COVID-19  
64 infection and hospitalization, with numbers doubling every ten days between July 1, 2021  
65 and August 9, 2021 (7,13), despite the high coverage of the BNT162b2 vaccine in Israel  
66 during this period—greater than 75% coverage with two Pfizer doses in the eligible  
67 population (individuals  $\geq 12$  years of age) (13).

68

69 The rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence,  
70 and the imminent risk of hospital overcrowding, led the Israeli government to initialize on  
71 July 30, 2021, an unparalleled, pro-active, national third (booster) vaccine shot campaign,  
72 offering the BNT162b2 mRNA COVID-19 vaccine to individuals over the age of 60. On  
73 August 13, 2021, the booster campaign was expanded to include those over 50 years of  
74 age, reaching 63% third-dose coverage among the eligible population within only 26 days  
75 (7,14–16). Two weeks later, on August 29, 2021, the campaign was expanded to include  
76 all individuals 16+ of age, demanding only that five months have passed since the receipt  
77 of the second dose, reaching 40% third-dose coverage among the eligible population under  
78 50 years of age, within 16 days (13,17).

79

80 Currently, limited information is available on the safety of a BNT162b2 third dose (18,19),  
81 with such a booster vaccine yet to be authorized by the US Food and Drug Administration  
82 (FDA) to the general population (20). While recent evidence shows that a third BNT162b2

83 dose in immunocompromised individuals has a favorable safety profile (19,21), the safety  
84 of a third (booster) dose in the general population has not yet been fully established.

85

86 Here, we evaluate the short-term effects of a third BNT162b2 mRNA COVID-19 vaccine  
87 dose on self-reported and physiological indicators. We followed a cohort of 2,912  
88 participants; of these, 1,609 participants received at least one dose of the BNT162b2  
89 vaccine after joining the study. Each participant received a dedicated mobile application  
90 and a Garmin Vivosmart 4 smartwatch. The mobile application collected daily self-  
91 reported questionnaires on local and systemic reactions as well as various well-being  
92 indicators. The smartwatch continuously monitored several physiological measures,  
93 including heart rate, heart rate variability (HRV) and blood oxygen saturation level. Our  
94 analysis of the comprehensive data on each participant examines the safety of a third  
95 (booster) vaccine dose from both a subjective perspective (patient questionnaire) and an  
96 objective perspective (smartwatch data).

97

## 98 **Materials and Methods**

### 99 **Study design and participants**

100 Our study includes a prospective cohort of 2,912 participants (18+ years of age) who were  
101 recruited between November 1, 2020 and September 15, 2021. The 1,609 participants who  
102 reported receipt of at least one of the three BNT162b2 mRNA COVID-19 vaccine shots  
103 after joining the study served as the base cohort for our analysis. Specifically, of these  
104 1,609 participants, during the study, 223 received their first dose, 351 their second dose,  
105 and 1,344 their third dose.

106

107 We employed a professional survey company to recruit participants and ensure they follow  
108 through with the study requirements. Participant recruitment was performed via  
109 advertisements on social media and word-of-mouth. Each participant provided informed  
110 consent by signing a form after receiving a comprehensive explanation on the study. Then,  
111 participants completed a one-time enrollment questionnaire, were equipped with Garmin  
112 Vivosmart 4 smartwatches, and installed two applications on their mobile phones: (1) the  
113 PerMed application (22) that collected daily self-reported questionnaires, and (2) an  
114 application that passively recorded the smartwatch data. Participants were asked to wear  
115 their smartwatches as much as possible. The survey company ensured that participants'  
116 questionnaires were completed daily, that their smartwatches were charged and properly  
117 worn, and that any technical problems with the mobile applications or smartwatch were  
118 resolved.

119

### 120 **PerMed mobile application**

121 Participants used the PerMed mobile application (22) to fill out daily questionnaires. The  
122 questionnaire allowed participants to report various well-being indicators, including mood  
123 level (on a scale of 1 [awful] to 5 [excellent]), stress level (on a scale of 1 [very low] to 5  
124 [very high]), sport duration (in minutes), and sleep quality (on a scale of 1 [awful] to 5  
125 [excellent]). The questionnaire also collected data on clinical symptoms consistent with the  
126 local and systemic reactions observed in the BNT162b2 mRNA Covid-19 clinical trial (23),  
127 with an option to add other symptoms as free text. (For more details see Appendix A in the  
128 Supplemental Material)

129

130 We implemented preventive measures to improve the quality, continuity, and reliability of  
131 the collected data. Each day, if by 7 pm, participants had not yet filled out the daily  
132 questionnaire, they received a reminder notification through the PerMed application.  
133 Furthermore, we used a dedicated dashboard to identify participants who continually  
134 neglected to complete the daily questionnaires; these participants were contacted by the  
135 survey company and were encouraged to better adhere to the study protocol.

136

137

### 138 **The smartwatch**

139 Participants were equipped with Garmin Vivosmart 4 smart fitness trackers. Among other  
140 features, the smartwatch provides all-day heart rate and heart rate variability and during-  
141 night blood oxygen saturation level tracking capabilities (24).

142

143 The optical wrist heart rate (HR) monitor of the smartwatch is designed to continuously  
144 monitor a user's heart rate. The frequency at which heart rate is measured varies and may  
145 depend on the level of activity of the user: when the user starts an activity, the optical HR  
146 monitor's measurement frequency increases.

147

148 Since heart rate variability (HRV) is not easily accessible through Garmin's application  
149 programming interface (API), we use Garmin's stress level instead, which is calculated  
150 based on HRV. Specifically, the device uses heart rate data to determine the interval  
151 between each heartbeat. The variable length of time between each heartbeat is regulated by

152 the body's autonomic nervous system. Less variability between beats correlates with higher  
153 stress levels, whereas an increase in variability indicates less stress (25). A similar  
154 relationship between HRV and stress was also seen in (26,27).

155

156 The Pulse Ox monitor of the smartwatch uses a combination of red and infrared lights with  
157 sensors on the back of the device to estimate the percentage of oxygenated blood  
158 (peripheral oxygen saturation, SpO<sub>2</sub>%). The Pulse Ox monitor is activated each day at a  
159 fixed time for a period of four hours (the default is 2AM-6AM).

160

161 Examining the data collected in our study, we identified an HR sample roughly every 15  
162 seconds, an HRV sample every 180 seconds, and an SpO<sub>2</sub> sample every 60 seconds.

163

164 While the Garmin smartwatch provides state-of-the-art wrist monitoring, it is not a  
165 medical-grade device, and some readings may be inaccurate under certain circumstances,  
166 depending on factors such as the fit of the device and the type and intensity of the activity  
167 undertaken by a participant (28–30).

168

### 169 **Statistical analysis**

170 Questionnaire data were preprocessed by manually categorizing any self-reported  
171 symptom entered as free text. In addition, if participants filled out the questionnaire more  
172 than once in one day, the last entry from that day was used in the analysis. Smartwatch data  
173 were preprocessed as follows. First, we computed the mean value of each hour of data. We



174 then performed linear interpolation to impute missing hourly means. Lastly, we smoothed  
175 the data by calculating the five-hour moving average.

176

177 For each participant, we defined the 7-day period prior to vaccination as the baseline  
178 period. We noted any pre-existing clinical symptoms from the last questionnaire completed  
179 during the baseline period. Next, we calculated the percentage of participants who reported  
180 new (that is, not pre-existing) systemic reactions in the 48 hours after vaccination. For each  
181 reaction, we used a beta distribution to determine a 90% confidence interval. To determine  
182 the statistical significance of differences between the first and third doses and between the  
183 second and third doses as reflected by the extent of reported reactions, a two proportion Z-  
184 test was used.

185

186 We also calculated the mean difference in well-being indicators between the post-  
187 vaccination period and the baseline period. Specifically, for each indicator, for each of the  
188 three days post-vaccination, and for each participant, we calculated the difference between  
189 that indicator's value and its corresponding value in the baseline period. Then, we  
190 calculated the mean value over all participants and the associated 90% confidence interval.

191

192 To compare the changes in smartwatch physiological indicators over the seven days (168  
193 hours) post vaccination with those of the baseline period, we performed the following steps.  
194 First, for each participant and each hour during the seven days post vaccination, we  
195 calculated the difference between that hour's indicator value and that of the corresponding  
196 hour in the baseline period (keeping the same day of the week and same hour during the

197 day). Then, we aggregated each hour's differences over all participants to calculate a mean  
198 difference and associated 90% confidence interval, which is analogous to a one-sided t-test  
199 with significance level 0.05. To determine the statistical significance of differences  
200 between the first and third doses and between the second and third doses as reflected by  
201 changes in smartwatch indicators during the 48 hours post-vaccination, we used a two-  
202 sample t-test with unequal variance.

203

204 We repeated the above analyses for the third dose stratified by age groups (<50, 50-64, and  
205  $\geq 65$ ), gender and the existence of an underlying medical condition (present vs. not present)  
206 from the list specified in Table 1.

207

## 208 **Ethical Approval**

209 Before participating in the study, all subjects were advised, both orally and in writing, as  
210 to the nature of the study and gave written informed consent. The study was approved by  
211 MHS' Helsinki institutional review board, protocol number 0122-20-MHS.

212

## 213 **Results**

214 Of the 1,609 participants who received at least one dose of the BNT162b2 vaccine after  
215 joining the study, 854 (53.08%) were women, and 755 (46.92%) were men. Their age  
216 ranged between 18 and 88 years, with a median age of 52 (Table 1). 1,258 (78.19%)  
217 participants had a body mass index below 30, and 412 (25.61%) had at least one specific  
218 underlying medical condition (Table 1). The distributions of age and gender and the

219 existence of underlying medical conditions were relatively invariable across the recipients  
 220 of the first, second and third dose (Table 1).  
 221

**Table 1.** Characteristics of the participants

<b>Characteristic</b>	<b>All Participants (N=1,609)</b>	<b>First Dose (N=223)</b>	<b>Second Dose (N=351)</b>	<b>Third Dose (N=1,344)</b>
<b>Gender</b>				
Male	46.92% (755)	45.29% (101)	45.58% (160)	47.54% (639)
Female	53.08% (854)	54.71% (122)	54.42% (191)	52.46% (705)
<b>Age group</b>				
18-29 yr	14.23% (229)	6.28% (14)	11.11% (39)	14.06% (189)
30-39 yr	16.9% (272)	4.93% (11)	15.1% (53)	16.29% (219)
40-49 yr	11.0% (177)	6.73% (15)	11.97% (42)	10.27% (138)
50-59 yr	26.1% (420)	28.7% (64)	24.79% (87)	27.9% (375)
60-69 yr	22.25% (358)	31.39% (70)	21.37% (75)	22.92% (308)
≥ 70 yr	9.51% (153)	21.97% (49)	15.67% (55)	8.56% (115)
<b>Body-mass index*</b>				
< 30.0	78.19% (1,258)	78.48% (175)	79.77% (280)	77.68% (1,044)
≥ 30.0	20.51% (330)	18.39% (41)	17.09% (60)	21.43% (288)
Unspecified	1.31% (21)	3.14% (7)	3.13% (11)	0.89% (12)
<b>Underlying Medical Condition</b>				
Hypertension	14.17% (228)	20.63% (46)	15.95% (56)	14.43% (194)

Diabetes	8.64% (139)	13% (29)	7.98% (28)	8.41% (113)
Heart disease	4.79% (77)	7.17% (16)	4.56% (16)	4.99% (67)
Chronic lung disease	5.03% (81)	4.93% (11)	3.7% (13)	5.21% (70)
Immune suppression	0.81% (13)	1.35% (3)	0.85% (3)	0.89% (12)
Cancer	0.62% (10)	0.45% (1)	0.57% (2)	0.67% (9)
Renal failure	0.5% (8)	1.79% (4)	1.42% (5)	0.45% (6)
None of the above	73.34% (1,180)	64.57%	72.08% (253)	73.21% (984)
		(144)		
Unspecified	1.06% (17)	1.35% (3)	2.85% (10)	0.52% (7)


---

\* The body-mass index is the weight in kilograms divided by the square of the height in meters

222

223 Our examination of self-reported reactions revealed that the extent of systemic reactions  
 224 reported following the third vaccine dose are similar to those reported following the second  
 225 dose (p-value=0.305), and considerably greater than those observed following the first dose  
 226 (p-value<0.001) (Figure 1). Specifically, 60.4% (90% CI: 57.9-62.9%) of the participants  
 227 did not report any new symptoms after receiving the third dose, compared to 86.5% (90%  
 228 CI: 81.9-91.0%) and 63.6% (90% CI: 59.1-67.8%) after the first and second doses,  
 229 respectively. Moreover, the most frequently reported types of reactions—fatigue,  
 230 headache, muscle pain, fever, and chills—were similar after the second and third doses.  
 231 These reactions faded in nearly all participants within three days (Figure S8 in the  
 232 Supplemental Material). Notably, these trends are consistent with those reported in the first  
 233 and second dose BNT162b2 mRNA vaccine clinical trial (23).

234



235

236 **Figure 1. Reactions reported by participants through the mobile application.** The bars

237 represent the percentage of participants who reported a given symptom. Error bars represent 90%

238 confidence intervals.

239

240 For the self-reported well-being indicators (Fig. 2), we found that during the first two days

241 after the third vaccine dose, participants exhibited a significant reduction in mood level


242 (Fig. 2A), sport duration (Fig. 2C), sleep quality (Fig. 2D) and a notable increase in stress

243 level (Fig. 2B) compared to baseline levels. These changes faded away on the third day

244 post vaccination. A similar trend can be observed after the second vaccine dose, except for

245 the reported stress level that remains below the baseline level during the second and third

246 days post-vaccination.




247

248 **Figure 2. Changes in subjective well-being indicators reported by participants through the**  
249 **mobile application.** Mean difference compared to baseline levels for the well-being indicators of  
250 (A) Mood level, (B) Stress level, (C) Sport duration, and (D) Sleep quality. Mood level, Stress  
251 level, and Sleep quality were reported on a 1-5 Likert scale. Sport duration was measured in  
252 minutes. Error bars represent 90% confidence intervals. Horizontal dashed lines represent no  
253 change compared to baseline levels.

254

255 We observed similar trends when analyzing the objective and continuous physiological  
256 measurements collected by the smartwatch (Fig. 3 below and Fig. S1 in the Supplemental  
257 Material). Specifically, we identified a considerable rise in both the heart rate (Fig. 3A-C)  
258 and the heart rate variability-based stress (Fig. 3D-F) indicators in the first 48 hours  
259 following the administration of the third dose. Measurements returned to their baseline  
260 levels within 72 hours. By contrast, our analysis of blood oxygen saturation levels suggests

261 that there are no apparent changes following inoculation compared to baseline levels (Fig.  
262 3G-I). The trends observed for the objective heart rate (HR) and heart rate variability  
263 (HRV) indicators were consistent with those of the subjective indicators in the following  
264 sense - similar changes following the second and third doses (HR p-value=0.43, HRV p-  
265 value=0.28), and greater changes following the second and third doses than the first dose  
266 (HR p-value<0.03, HRV p-value<0.01).  
267



268  
269 **Figure 3. Changes in objective physiological indicators measured through the smartwatch.**  
270 Mean difference in smartwatch-recorded (A-C) heart rate, (D-F) heart rate variability-based stress  
271 and (G-I) blood oxygen saturation level (SpO2) following the first, second and third dose,  
272 compared to their baseline levels. Mean values are depicted as solid lines; 90% confidence intervals


273 are presented as shaded regions. The horizontal dashed line represents no change compared to the  
274 baseline levels, and vertical lines represent 24-hour periods.

275

276 We also stratified our analyses of well-being and smartwatch physiological indicators after  
277 the third vaccination by age group, gender, and the existence of a prior underlying medical  
278 condition (Fig. 4 below and Fig. S2-S7 in the Supplemental Material). For all  
279 stratifications, trends were similar to those observed in the general population. Namely,  
280 there were considerable changes in the two days after vaccine administration that faded  
281 almost entirely after three days. We also found that participants 65+ years reported fewer  
282 reactions ( $p$ -value $<0.001$ ) and exhibited milder physiological changes compared to those  
283 between 50-65 years (HR  $p$ -value=0.02, HRV  $p$ -value=0.07), and participants between 50-  
284 65 years reported even fewer reactions ( $p$ -value $<0.01$ ) and exhibited milder physiological  
285 changes in heart rate (HR  $p$ -value=0.02), compared to those below 50 years (Figure 4A-  
286 B). Male participants reported fewer reactions ( $p$ -value $<0.001$ ) but did not exhibit milder  
287 physiological changes (HR  $p$ -value=0.37, HRV  $p$ -value=0.59) than female participants.  
288 Participants with an underlying medical condition reported fewer reactions ( $p$ -  
289 value $<0.001$ ) and exhibited milder physiological changes (HR  $p$ -value=0.04, HRV  $p$ -  
290 value=0.16), compared to those without an underlying medical condition. Markedly, out  
291 of 9 participants who reported dyspnea 4 (0.96% of their age group) were below 50 years,  
292 4 (0.93% of their age group) were between 50-64 years and 1 (0.65% of her age group)  
293 was 65+ years. One participant below 50 years reported chest pain following inoculation.  
294 None of these participants had underlying medical condition. These reactions (i.e., dyspnea  
295 and chest pain) disappeared between 2-4 days following inoculation.



296



297 **Figure 4. Self-reported and objective reactions following the third vaccine dose, stratified by**  
 298 **age, gender and the existence of an underlying medical condition.** Reactions reported by  
 299 participants through the mobile application, stratified by age (A), gender (B) and underlying  
 300 medical condition (E). The bars represent the percentage of participants who reported a given  
 301 symptom. Error bars represent 90% confidence intervals. Changes in objective heart rate and heart  
 302 rate variability measured through the smartwatch in the 48 hours post-vaccination, stratified by age  
 303 (B), gender (D) and underlying medical condition (F).

304

### 305 Discussion

306 Our key findings suggest that local and systemic reactions reported following the third  
 307 (booster) vaccine dose administration are very similar to those reported following the  
 308 second dose and considerably greater than those observed following the first dose. Our

309 analyses of both self-reported well-being indicators and objective smartwatch  
310 physiological indicators underscore these results. Furthermore, within three days from  
311 inoculation with the third dose, all measures returned to their baseline levels in nearly all  
312 participants.

313

314 We identified differences in subpopulations based on gender, age and underlying medical  
315 condition following administration of the third vaccine dose. It has been previously  
316 suggested that reactions caused by the COVID-19 vaccine are a byproduct of a short burst  
317 of IFN-I generation concomitant with induction of an effective immune response (31). IFN-  
318 I generation is substantially stronger in females than in males and stronger in younger and  
319 healthier individuals than in older and less healthy ones. We found that participants below  
320 the age of 65, females, and those without an underlying medical condition experienced  
321 greater reactions both in self-reported local and systemic reactions and well-being  
322 indicators as well as in objective physiological measurements recorded by the smartwatch.  
323 Our results are also in line with a previous study that found similar trends after the first and  
324 second doses (32).

325

326 Clinical trials have not yet capitalized on the comprehensive physiological measures  
327 generated by wearables. Currently, the FDA and European Medicines Agency (EMA)  
328 evaluate the safety and create guidelines for newly developed vaccines primarily based on  
329 subjective, self-reported questionnaires (33,34). Much of the scientific literature discusses  
330 these self-reported side effects of COVID-19 vaccines. However, integrating wearables

331 into clinical trials, alongside self-reported questionnaires, can provide more precise and  
332 rich data regarding the vaccines' effects on physiological measures.

333

334 Our study has several limitations. First, the 1,609 individuals who comprise the base cohort  
335 of our analyses may not be representative of the vaccinated population in Israel or globally.  
336 Nevertheless, the changes observed in self-reported reactions and well-being indicators as  
337 well as objective physiological indicators recorded by the smartwatches were statistically  
338 significant and consistent with each other. Moreover, the reaction types, frequency and  
339 duration we observed for the first and second dose were similar to those observed in the  
340 BNT162b2 mRNA vaccine clinical trials (23). In addition, a clear pattern of returning to  
341 baseline levels was observed within 72 hours post inoculation in all examined measures.  
342 Lastly, although the sample size was limited, trends were consistent regardless of age  
343 group, gender, and the existence of underlying medical conditions.

344

345 Second, we did not explicitly control for the effects of the observational trial setting (i.e.,  
346 participating in a trial, wearing a smartwatch, potential concerns regarding the vaccine,  
347 etc.). Any effects of the observational trial setting should, in principle, have similar impacts  
348 on our analysis of each of the three vaccine doses. However, since we found no deviations  
349 in most measurements from baseline levels in the subset of participants who received their  
350 first dose, we believe the changes observed after the second and third doses arise from an  
351 actual reaction to the vaccine.

352

353 Third, the smartwatches used to obtain physiological measurements are not medical-grade  
354 devices. Nevertheless, recent studies show a considerably accurate heart rate  
355 measurement in the previous versions of the smartwatch used in this study (28,29).  
356 Moreover, our analysis focused on the change in measurements compared to their baseline  
357 values rather than on their absolute values.

358

359 Finally, the only vaccine available in Israel is the BNT162b2 mRNA vaccine. Although  
360 our findings may not directly generalize to other types of COVID-19 vaccines, we believe  
361 that applying our analyses on other vaccines are likely to yield qualitatively similar  
362 findings, due to the similarities observed between different COVID-19 vaccines  
363 (23,35,36).

364

365 Our study strengthens the evidence regarding the short-term safety of the booster  
366 BNT162b2 vaccine in several ways. First, reports of local and systemic reactions following  
367 the third dose were very similar to those observed following the second dose, which was  
368 already shown in clinical trials to be safe (23). Second, the considerable changes observed  
369 in all indicators during the first two days after receiving the third vaccine, including self-  
370 reported reactions and well-being indicators as well as objective physiological indicators  
371 collected by the smartwatch, returned to their baseline levels. Third, regardless of the  
372 observed differences between subpopulations, our analyses indicate a clear pattern of  
373 return to baseline levels in all considered subpopulations. Fourth, we observed no change  
374 in blood oxygen saturation levels compared to baseline levels, indicating that major adverse  
375 health consequences are less likely.

376 In conclusion, our study supports the short-term safety of the third BNT162b2 mRNA  
377 COVID-19 (booster) vaccine dose and mitigates, in part, concerns regarding its short-term  
378 effects. The medical and scientific communities could greatly benefit from the largely  
379 unbiased data generated by digital health technologies such as the wearable data which we  
380 analyzed in this study. Our findings could also be of interest to public health officials and  
381 other stakeholders, as it is important that objective measures are given attention in the  
382 critical evaluation of clinical trials.

383 **References**

- 384 1. Kupferschmidt K, Wadman M. Delta variant triggers new phase in the pandemic.  
385 Science (80- ) [Internet]. 2021 Jun 25 [cited 2021 Aug 22];372(6549):1375–6.  
386 Available from: <https://science.sciencemag.org/content/372/6549/1375>
- 387 2. Tracking SARS-CoV-2 variants [Internet]. [cited 2021 Aug 22]. Available from:  
388 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants>
- 389 3. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2  
390 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and  
391 vaccine breakthrough. bioRxiv [Internet]. 2021 Aug 6 [cited 2021 Aug  
392 22];2021.05.08.443253. Available from:  
393 <https://www.biorxiv.org/content/10.1101/2021.05.08.443253v5>
- 394 4. Delta Variant: What We Know About the Science | CDC [Internet]. [cited 2021  
395 Aug 22]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html>
- 396
- 397 5. Mahase E. Delta variant: What is happening with transmission, hospital  
398 admissions, and restrictions? BMJ [Internet]. 2021 Jun 15 [cited 2021 Aug  
399 22];373:n1513. Available from: <https://www.bmj.com/content/373/bmj.n1513>
- 400 6. Weekly epidemiological update on COVID-19 - 17 August 2021 [Internet]. [cited  
401 2021 Aug 22]. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---17-august-2021>
- 402
- 403 7. Wadman M. Israel’s grim warning: Delta can overwhelm shots. Science (80- )

- 404 [Internet]. 2021 Aug 20 [cited 2021 Aug 22];373(6557):838–9. Available from:  
405 <https://science.sciencemag.org/content/373/6557/838>
- 406 8. Munitz A, Yechezkel M, Dickstein Y, Yamin D, Gerlic M. BNT162b2 vaccination  
407 effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk  
408 populations in Israel. *Cell Reports Med* [Internet]. 2021 Apr [cited 2021 May  
409 3];0(0):100264. Available from:  
410 <https://linkinghub.elsevier.com/retrieve/pii/S266637912100080X>
- 411 9. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.  
412 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.  
413 <https://doi.org/101056/NEJMoa2108891> [Internet]. 2021 Jul 21 [cited 2021 Aug  
414 22];385(7):585–94. Available from:  
415 <https://www.nejm.org/doi/full/10.1056/NEJMoa2108891>
- 416 10. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al.  
417 Impact of Delta on viral burden and vaccine effectiveness against new SARS-  
418 CoV-2 infections in the UK.
- 419 11. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in  
420 Scotland: demographics, risk of hospital admission, and vaccine effectiveness.  
421 *Lancet* [Internet]. 2021 Jun 26 [cited 2021 Aug 22];397(10293):2461–2. Available  
422 from: <http://www.thelancet.com/article/S0140673621013581/fulltext>
- 423 12. Nasreen S, He Msc S, Mph HC, Brown Phd KA, Gubbay JB, Buchan SA, et al.  
424 Effectiveness of COVID-19 vaccines against variants of concern, Canada on  
425 behalf of the Canadian Immunization Research Network (CIRN) Provincial

- 426 Collaborative Network (PCN) Investigators. [cited 2021 Aug 22]; Available from:  
427 <https://doi.org/10.1101/2021.06.28.21259420>
- 428 13. COVID-19 Datasets- Government Data [Internet]. [cited 2020 May 30]. Available  
429 from: <https://data.gov.il/dataset/covid-19>
- 430 14. The Ministry of Health Director General Has Approved the Recommendation to  
431 Administer a Third Vaccine Dose to 50-Year-Olds and Older and to Other  
432 Populations | Ministry of Health [Internet]. [cited 2021 Aug 22]. Available from:  
433 <https://www.gov.il/en/departments/news/13082021-01>
- 434 15. The Vaccination Advisory Committee Presented Data and Recommended the  
435 Administration of a Third Dose to Older Adults | Ministry of Health [Internet].  
436 [cited 2021 Aug 22]. Available from:  
437 <https://www.gov.il/en/departments/news/29072021-04>
- 438 16. Statement by PM Bennett on Third Dose of the COVID Vaccine to Israeli Citizens  
439 over the Age of 60 | Prime Minister's Office [Internet]. [cited 2021 Aug 22].  
440 Available from: [https://www.gov.il/en/Departments/news/event\\_press290721](https://www.gov.il/en/Departments/news/event_press290721)
- 441 17. The Vaccination Policy and the New Green Pass that will Take Effect Soon |  
442 Ministry of Health [Internet]. [cited 2021 Sep 15]. Available from:  
443 <https://www.gov.il/en/departments/news/29082021-01>
- 444 18. Joint Statement from HHS Public Health and Medical Experts on COVID-19  
445 Booster Shots | CDC Online Newsroom | CDC [Internet]. [cited 2021 Aug 22].  
446 Available from: [https://www.cdc.gov/media/releases/2021/s0818-covid-19-](https://www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html)  
447 [booster-shots.html](https://www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html)



- 448 19. COVID-19 Vaccines for Moderately to Severely Immunocompromised People |  
449 CDC [Internet]. [cited 2021 Aug 22]. Available from:  
450 [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html)  
451 [ncov/vaccines/recommendations/immuno.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html)
- 452 20. Joint Statement from HHS Public Health and Medical Experts on COVID-19  
453 Booster Shots | FDA [Internet]. [cited 2021 Aug 23]. Available from:  
454 [https://www.fda.gov/news-events/press-announcements/joint-statement-hhs-](https://www.fda.gov/news-events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-covid-19-booster-shots)  
455 [public-health-and-medical-experts-covid-19-booster-shots](https://www.fda.gov/news-events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-covid-19-booster-shots)
- 456 21. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Bello A Del. Three Doses of  
457 an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.  
458 <https://doi.org/10.1056/NEJMc2108861> [Internet]. 2021 Jun 23 [cited 2021 Aug  
459 23];385(7):661–2. Available from:  
460 <https://www.nejm.org/doi/10.1056/NEJMc2108861>
- 461 22. Oved S, Mofaz M, Lan A, Einat H, Kronfeld-Schor N, Yamin D, et al. Differential  
462 effects of COVID-19 lockdowns on well-being: interaction between age, gender  
463 and chronotype [Internet]. 2021 Jan [cited 2021 Mar 31]. Available from:  
464 <https://www.researchsquare.com>
- 465 23. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety  
466 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*  
467 [Internet]. 2020 Dec 31 [cited 2021 Mar 31];383(27):2603–15. Available from:  
468 <http://www.nejm.org/doi/10.1056/NEJMoa2034577>
- 469 24. VÍVOSMART ® 4 Owner’s Manual. 2018 [cited 2021 Aug 23]; Available from:

- 470 [www.garmin.com](http://www.garmin.com)
- 471 25. What Is the Stress Level Feature on My Garmin Watch? | Garmin Support  
472 [Internet]. [cited 2021 Aug 24]. Available from: [https://support.garmin.com/en-](https://support.garmin.com/en-US/?faq=WT9BmhjacO4ZpxbCc0EKn9)  
473 [US/?faq=WT9BmhjacO4ZpxbCc0EKn9](https://support.garmin.com/en-US/?faq=WT9BmhjacO4ZpxbCc0EKn9)
- 474 26. Kim H-G, Cheon E-J, Bai D-S, Lee YH, Koo B-H. Stress and Heart Rate  
475 Variability: A Meta-Analysis and Review of the Literature. *Psychiatry Investig*  
476 [Internet]. 2018 Mar 1 [cited 2021 Aug 24];15(3):235. Available from:  
477 [/pmc/articles/PMC5900369/](https://pubmed.ncbi.nlm.nih.gov/30530451/)
- 478 27. Pereira T, Almeida PR, Cunha JPS, Aguiar A. Heart rate variability metrics for  
479 fine-grained stress level assessment. *Comput Methods Programs Biomed*. 2017  
480 Sep 1;148:71–80.
- 481 28. RK R, R P, DP Z, B S, J EY, E D, et al. Accuracy of Wrist-Worn Activity  
482 Monitors During Common Daily Physical Activities and Types of Structured  
483 Exercise: Evaluation Study. *JMIR mHealth uHealth* [Internet]. 2018 Dec 1 [cited  
484 2021 Aug 23];6(12). Available from: <https://pubmed.ncbi.nlm.nih.gov/30530451/>
- 485 29. Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in  
486 wearable optical heart rate sensors. *npj Digit Med* 2020 31 [Internet]. 2020 Feb 10  
487 [cited 2021 Aug 23];3(1):1–9. Available from:  
488 <https://www.nature.com/articles/s41746-020-0226-6>
- 489 30. Accuracy | Garmin [Internet]. [cited 2021 Aug 22]. Available from:  
490 <https://www.garmin.com/en-US/legal/atdisclaimer/>

- 491 31. Bunders MJ, Altfeld M. Implications of Sex Differences in Immunity for SARS-  
492 CoV-2 Pathogenesis and Design of Therapeutic Interventions. *Immunity*. 2020 Sep  
493 15;53(3):487–95.
- 494 32. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-  
495 effects and SARS-CoV-2 infection after vaccination in users of the COVID  
496 Symptom Study app in the UK: a prospective observational study. *Lancet Infect  
497 Dis* [Internet]. 2021 Jul 1 [cited 2021 Aug 24];21(7):939–49. Available from:  
498 <http://www.thelancet.com/article/S1473309921002243/fulltext>
- 499 33. Development and Licensure of Vaccines to Prevent COVID-19 | FDA [Internet].  
500 [cited 2021 Mar 31]. Available from: [https://www.fda.gov/regulatory-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19)  
501 [information/search-fda-guidance-documents/development-and-licensure-vaccines-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19)  
502 [prevent-covid-19](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19)
- 503 34. Clinical trials in human medicines | European Medicines Agency [Internet]. [cited  
504 2021 Aug 23]. Available from: [https://www.ema.europa.eu/en/human-](https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials-human-medicines)  
505 [regulatory/research-development/clinical-trials-human-medicines](https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials-human-medicines)
- 506 35. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy  
507 and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* [Internet].  
508 2021 Feb 4 [cited 2021 Mar 31];384(5):403–16. Available from:  
509 <http://www.nejm.org/doi/10.1056/NEJMoa2035389>
- 510 36. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.  
511 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-  
512 CoV-2: an interim analysis of four randomised controlled trials in Brazil, South

513 Africa, and the UK. Lancet [Internet]. 2021 Jan 9 [cited 2021 Mar  
514 31];397(10269):99–111. Available from: <https://doi.org/10.1016/>

515

#### 516 **Financial Support**

517 This research was supported by the European Research Council (ERC) project #949850  
518 and the Israel Science Foundation (ISF), grant No. 3409/19, within the Israel Precision  
519 Medicine Partnership program. MLB and GG received support from the Koret foundation  
520 grant for  
521 Smart Cities and Digital Living 2030.

522

#### 523 **Data availability**

524 Researchers interested in obtaining an aggregated version of the data sufficient to  
525 reproduce the results reported in this paper should contact the corresponding author.

526

#### 527 **Authors' contributions**

528 Conception and design: DY, ES. Collection and assembly of data: MM, TP, SG, ES.  
529 Analysis and interpretation of the data: MM, GG, MLB, DY, ES. Statistical expertise: MM,  
530 DY, ES. Drafting the article: MM, MY, DY, ES. Critical revision of the article for  
531 important intellectual content: DY, ES. Final approval of the article: All authors. Obtaining  
532 funding: DY, ES.

533

#### 534 **Disclosures**

535 All authors have disclosed no conflicts of interest.

536 **Reproducible Research Statement**

537 Further details are available from Dr. Erez Shmueli (e-mail, [shmueli@tau.ac.il](mailto:shmueli@tau.ac.il)).

538 Statistical code will be available after acceptance.

539   Supplementary Materials for:  
540    **Self-reported and physiological reactions to the third BNT162b2 mRNA**  
541   **COVID-19 (booster) vaccine dose**

542    Merav Mofaz, MSc<sup>1</sup>, Matan Yechezkel, MSc<sup>1</sup>, Grace Guan<sup>2</sup>, Margaret L. Brandeau, PhD<sup>2</sup>, Tal Patalon,  
543   MD<sup>3</sup>, Sivan Gazit, MD<sup>3</sup>, Dan Yamin, PhD<sup>1,4,+</sup>, and Erez Shmueli, PhD<sup>1,5,+,\*</sup>

544    <sup>1</sup>Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel.

545    <sup>2</sup>Department of Management Science and Engineering, Stanford University, Stanford CA, USA.

546    <sup>3</sup>Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.

547    <sup>4</sup>Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel.

548    <sup>5</sup>MIT Media Lab, Cambridge MA, USA.

549    <sup>+</sup>Equal contribution

550    \*Corresponding author. Email: shmueli@tau.ac.il

551 **Appendix A: Self-reported questionnaires**

552

553 *Enrollment questionnaire*

554 All participants will fill a one-time enrollment questionnaire that includes demographic questions  
555 and questions about the participant's health condition in general. Specifically, the questionnaire  
556 will include the following: age, gender, height, weight and underlying medical conditions (Listed  
557 in Table 1, main text). Other questions such as name, address, phone number and email will be  
558 recorded and used by the survey company to contact the participants. The answers will be filled-in  
559 directly by the survey company to the study's secured dashboard.

560

561 *Vaccination questionnaire*

562 The vaccination questionnaire we will use includes the following question:

- 563     ○ COVID-19 vaccination – date, time and dose number.

564

565 *Daily questionnaire*

566 All participants will complete the daily self-reported questionnaire in a dedicated application (the  
567 PerMed mobile application). The daily questionnaire we will use includes the following questions:

- 568     ○ How is your mood today? • Awful (1) • Bad (2) • OK (3) • Good (4) • Excellent (5)
- 569     ○ How would you describe the level of your stress during the last day? • Very Low (1) • Low  
570         (2) • Medium (3) • High (4) • Very high (5)
- 571     ○ How would you define your last night sleep quality? • Awful (1) • Bad (2) • OK (3) • Good  
572         (4) • Excellent (5)
- 573     ○ Try to remember how many minutes of sports activity you performed on the last day?

- 574       ○ Have you experienced one or more of the following symptoms in the last 24 hours? • My  
575            general feeling is good, and I have no symptoms • Heat measured above 37.5 • Cough •  
576            Sore throat • Runny nose • Headache • Shortness of breath • Muscle aches • Weakness /  
577            fatigue • Diarrhea • Nausea / vomiting • Chills • Confusion • Loss of sense of taste / smell  
578            • Other symptom.
- 579




580 **Appendix B: Additional Results**

581 **Changes in objective physiological indicators measured through the smartwatch following**  
582 **the three vaccine doses**

583 Changes in objective physiological indicators observed during the first two days after the second  
584 and third vaccine doses are similar, and considerably greater than those observed following the  
585 first dose.

586



587


588 **Figure S1. Changes in objective physiological indicators measured through the smartwatch during**  
589 **the first two days after vaccine. Mean difference in smartwatch-recorded heart rate and heart rate**  
590 **variability-based following the first, second and third dose, compared to their baseline levels.**

591 Changes in objective physiological indicators were calculated by subtracting the baseline values  
592 from the mean value of the first two days following the vaccine dose. Error bars represent 90%  
593 confidence intervals.

594

595 **Changes in reported well-being indicators – stratification by age group**

596 Changes in well-being observed during the first two days after the third vaccine dose were found  
597 to be higher for participants younger than 50 years compared to those between 50 and 65 years,  
598 and consequently higher than those older than 65 years, with the exception of reported stress level  
599 (Figure S2).




600

601 **Figure S2. Changes in well-being indicators reported by participants through the mobile application**  
602 **stratified by age group.** (A) mood level, measured on a 1-to-5 Likert scale. (B) Stress level,  
603 measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep quality,  
604 measured on a 1-to-5 Likert scale. Changes in well-being indicators were calculated by subtracting  
605 the baseline values from the daily values. Error bars represent 90% confidence intervals. Horizontal  
606 dashed lines represent no change compared to baseline levels.

607 **Changes in reported well-being indicators – stratification by gender**

608 Changes in well-being observed during the first two days after the third vaccine dose were found

609 to be similar for males and females (Figure S3).



610

611 **Figure S3. Changes in well-being indicators reported by participants through the mobile application**

612 **stratified by gender.** (A) mood level, measured on a 1-to-5 Likert scale. (B) Stress level, measured


613 on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep quality, measured on

614 a 1-to-5 Likert scale. Changes in well-being indicators were calculated by subtracting the baseline

615 values from the daily values. Error bars represent 90% confidence intervals. Horizontal dashed

616 lines represent no change compared to baseline levels.


617 **Changes in reported well-being indicators – stratification by underlying medical condition**  
618 Changes in mood level and sleep quality observed during the first two days after the third vaccine  
619 dose were found to be higher for participants without underlying medical conditions compared to  
620 those with underlying medical condition (Figure S4).



621  
622 **Figure S4. Changes in well-being indicators reported by participants through the mobile application**  
623 **stratified by underlying medical conditions.** (A) mood level, measured on a 1-to-5 Likert scale. (B)  
624 Stress level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep  
625 quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators were calculated by  
626 subtracting the baseline values from the daily values. Error bars represent 90% confidence intervals.  
627 Horizontal dashed lines represent no change compared to baseline levels.

628 **Changes in physiological indicators – stratification by age group**

629 Changes in physiological indicators after the third vaccine dose stratified by age group were  
630 consistent with those observed in the general population (considerable changes during the first two  
631 days after vaccine administration that faded nearly entirely after three days). These changes were  
632 found to be higher for participants younger than 50 years compared to those between 50 and 65  
633 years, and consequently higher than those older than 65 years (Figure S5).



634 **Figure S5. Changes in physiological indicators measured through the smartwatch stratified by age**  
635 **groups.** Mean difference in heart rate and heart rate variability-based stress indicators following the  
636 third dose, recorded by a smartwatch, compared to their baseline levels: (A and B) heart rate, (C  
637 and D) heart rate variability-based stress. Mean values are depicted as solid lines; 90% confidence  
638 intervals are presented as shaded regions. The horizontal dashed line represents no change  
639 compared to the baseline levels, and vertical lines represent 24-hour periods.


640 **Changes in physiological indicators – stratification by gender**

641 Changes in physiological indicators after the third vaccine dose stratified by gender were consistent

642 with those observed in the general population (considerable changes during the first two days after

643 vaccine administration that faded nearly entirely after three days). These changes were found to be

644 higher for females compared to males (Figure S6).



645 **Figure S6. Changes in physiological indicators measured through the smartwatch stratified by**

646 **gender.** Mean difference in heart rate and heart rate variability-based stress indicators following


647 the third dose, recorded by a smartwatch, compared to their baseline levels: (A and B) heart rate,

648 (C and D) heart rate variability-based stress. Mean values are depicted as solid lines; 90%

649 confidence intervals are presented as shaded regions. The horizontal dashed line represents no

650 change compared to the baseline levels, and vertical lines represent 24-hour periods.

651 **Changes in physiological indicators – stratification by underlying medical condition**  
652 Changes in physiological indicators after the third vaccine dose stratified by underlying medical  
653 condition were consistent with those observed in the general population (considerable changes  
654 during the first two days after vaccine administration that faded nearly entirely after three days).  
655 These changes were found to be higher for participants without underlying medical conditions  
656 compared to those with underlying medical condition (Figure S7).



657 **Figure S7. Changes in physiological indicators measured through the smartwatch stratified by**  
658 **underlying medical conditions.** Mean difference in heart rate and heart rate variability-based stress  
659 indicators following the third dose, recorded by a smartwatch, compared to their baseline levels:  
660 (A and B) heart rate, (C and D) heart rate variability-based stress. Mean values are depicted as solid  
661 lines; 90% confidence intervals are presented as shaded regions. The horizontal dashed line  
662 represents no change compared to the baseline levels, and vertical lines represent 24-hour periods.


663 **14 days analysis for self-reported local and systemic reactions after the third dose**

664 We observe a sharp decline in reported local and systemic reactions following three days after the

665 third vaccination dose, and nearly a complete halt within 14 days post-vaccination (Figure S8).

666 Fatigue and headache were the most frequent reactions reported and lasted longer than the other

667 reported reactions.



668

669 **Figure S8. Most frequent local and systemic reactions reported by participants through the mobile**

670 **application after the third dose. (A) fatigue, (B) muscle pain, (C) headache, (D) fever, and (E) chills.**

671 Error bars represent 90% confidence intervals.



672 **Number of participants receiving each vaccine dose**

673 1,609 participants reported receipt of at least one of the three BNT162b2 mRNA COVID-19  
674 vaccine shots after joining the study. Specifically, out of these 1,609 participants serving as the  
675 base cohort for our analyses, 223 received during the study period their first dose, 351 their second  
676 dose, and 1,344 their third dose (Table S1).

**Table S1.** Number of participants receiving each vaccine dose

<b>Dose administered</b>	<b>Number of participants (n)</b>
First dose only	25
Second dose only	127
Third dose only	1,228
All three doses	80
First and second doses	113
First and third doses	5
Second and third doses	31

677